[go: up one dir, main page]

HK1242990A1 - Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer - Google Patents

Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer Download PDF

Info

Publication number
HK1242990A1
HK1242990A1 HK18102509.0A HK18102509A HK1242990A1 HK 1242990 A1 HK1242990 A1 HK 1242990A1 HK 18102509 A HK18102509 A HK 18102509A HK 1242990 A1 HK1242990 A1 HK 1242990A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
combination therapy
ccr5 antagonists
antagonists alone
Prior art date
Application number
HK18102509.0A
Other languages
Chinese (zh)
Inventor
Niels Halama
Dirk JÄGER
Inka ZOERNIG
Niels Grabe
Original Assignee
Ruprecht-Karls-Universitat Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruprecht-Karls-Universitat Heidelberg filed Critical Ruprecht-Karls-Universitat Heidelberg
Publication of HK1242990A1 publication Critical patent/HK1242990A1/en

Links

HK18102509.0A 2014-10-27 2015-10-27 Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer HK1242990A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62/068,919 2014-10-27

Publications (1)

Publication Number Publication Date
HK1242990A1 true HK1242990A1 (en) 2018-07-06

Family

ID=

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
SG11201609770TA (en) Combination therapies for the treatment of cancer
IL276733A (en) Use of eribulin in the treatment of cancer
IL248455A0 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumours
EP3207162A4 (en) Combination therapy for use in cancer therapy
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
IL248767B (en) Trimethoxyphenyl-benzimidazole compound for use in the treatment of cancer
IL251903B (en) Apilimod for use in the treatment of colorectal cancer
IL247586A0 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
PL3253208T3 (en) Combination therapies for use in the treatment of breast cancer
IL246855A0 (en) Agents for use in the treatment of retinal inflammation
IL269121A (en) Usl-311 for use in the treatment of cancer
IL252493B (en) Compounds for use in the prevention or treatment of cancer
HK1242990A1 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
HK40018432A (en) Usl-311 for use in the treatment of cancer
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
HK40009824A (en) Pharmaceutical composition for use in the treatment of prostate pathologies
HK1237824A1 (en) Combination therapy for use in cancer therapy
HK1257141A1 (en) Varlitinib for use in the treatment of resistant or refractory cancer
EP3125903A4 (en) Method for use of homopiperazinium compounds in the treatment of cancer